Long-lasting Blood Pressure Reduction Achieved with Single Injection: KARDIA-1
A single injection of the investigational antihypertensive agent zilebesiran effectively lowers blood pressure in adults with mild to moderate hypertension for up to 6 months, according to the phase 2 KARDIA-1 study. The study showed sustained reductions in blood pressure and serum angiotensinogen levels, with potential to improve medication adherence and reduce cardiovascular risk. Zilebesiran is a subcutaneous RNA interference therapeutic that targets angiotensinogen synthesis. The study demonstrated promising results and zilebesiran is being further evaluated as an add-on therapy for hypertension treatment.
